Breast cancer that returns after CDK4/6 inhibitor treatment
Part of Cancer clinical trials.
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older, female (any menopause status) or male.
- You had early-stage breast cancer that is hormone receptor-positive (HR+) and HER2-negative.
- You have started or are about to start a CDK4/6 inhibitor (abemaciclib or ribociclib) with hormone therapy after your surgery. Treatment must have begun on or after January 1, 2021.
- Your tumor shows at least 1% staining for estrogen or progesterone receptors (ER or PgR positive), and your HER2 test is negative (score 0 or 1+, or 2+ but a negative FISH test).
- You are able to do normal daily activities with little or no help (ECOG score 0, 1, or 2).
- You agree to let your data be used according to local rules.
- You are not currently in another trial for early breast cancer with an experimental drug.
- You have not had a CDK4/6 inhibitor before as part of a research study.
- You have had no other cancer in the past 5 years, except for non-melanoma skin cancer or cervical carcinoma in situ.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
This study compares two hormone therapy approaches for advanced breast cancer that has returned after completing at least one year of a CDK4/6 inhibitor (like abemaciclib or ribociclib) taken with hormone therapy. It aims to see if a different hormone therapy combination works better than the doctor's choice of treatment.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Hear when a new Adjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.